Omalizumab: Practical considerations regarding the risk of anaphylaxis

Allergy, Asthma and Clinical Immunology

Volumn 6, Issue 1, 2010, Pages

  Kim, Harold L ^a,b   Leigh, Richard ^c   Becker, Allan ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB; SALBUTAMOL;

ALLERGIC ASTHMA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRONCHOSPASM; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INFORMED CONSENT; MEDICATION THERAPY MANAGEMENT; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; REPEATED DRUG DOSE; REVIEW; SYNCOPE; URTICARIA;

EID: 79960001781     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-6-32     Document Type: Review

References (35)

1. Novartis Pharmaceuticals Canada Inc Xolair Prescribing Information. Date of Revision, February 10, 2010. Novartis Pharmaceuticals Canada Inc.
2. Global Initiative for Asthma Global Strategy for Asthma Management and Prevention. Updated December 2009. Global Initiative for Asthma., http://www.ginasthma.org
3. Lougheed MD, Lemière C, Dell SD, et al. Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for children six years of age and over, and adults. Can Respir J 2010, 17:15-24.
4. Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004, 59:701-8. 10.1111/j.1398-9995.2004.00533.x, 15180756.
5. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005, 60:302-8. 10.1111/j.1398-9995.2004.00770.x, 15679714.
6. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002, 20:73-8. 10.1183/09031936.02.00278102, 12166585.
7. Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002, 20:1088-94. 10.1183/09031936.02.00016502, 12449159.
8. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-90. 10.1067/mai.2001.117880, 11496232.
9. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003, 111:278-84. 10.1067/mai.2003.54, 12589345.
10. Holgate ST, Chuchalin AG, Hébert J, et al. for the Omalizumab 011 International Study Group Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-8. 10.1111/j.1365-2222.2004.1916.x, 15080818, for the Omalizumab 011 International Study Group.
11. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-16. 10.1111/j.1398-9995.2004.00772.x, 15679715.
12. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003, 91:154-9. 10.1016/S1081-1206(10)62170-9, 12952109.
13. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-61.
14. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004, 59:709-17. 10.1111/j.1398-9995.2004.00550.x, 15180757.
15. Chapman KR, Cartier A, Hébert J, et al. The role of omalizumab in the treatment of severe allergic asthma. Can Respir J 2006, 13(Suppl B):1B-9B. 2806789, 16909166.
16. Balter MS, Bell AD, Kaplan AG, et al. Management of asthma in adults. CMAJ 2009, 181:915-22. 2789128, 19786471.
17. Chapman KR, McIvor A. Asthma that is unresponsive to usual care. CMAJ 2010, 182:45-52.
18. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007, http://www.nhlbi.nih.gov
19. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med 2006, 47:373-80. 10.1016/j.annemergmed.2006.01.018, 16546624.
20. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007, 120:1373-7. 10.1016/j.jaci.2007.09.032, 17996286.
21. Novartis Pharmaceuticals Canada Inc Data on file from the XHALE program. Compiled December, 2009. Novartis Pharmaceuticals Canada Inc.
22. Steele RH, Limaye S, Cleland B, et al. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 2005, 10:317-20. 10.1111/j.1440-1797.2005.00389.x, 15958049.
23. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007, 28:313-9. 10.2500/aap.2007.28.3003, 17619560.
24. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009, 39:271-9. 10.1111/j.1365-2222.2008.03121.x, 19016798.
25. Lanier BQ. Unanswered Questions and Warnings Involving Anti-Immunoglobulin E Therapy Based on 2-Year Observation of Clinical Experience. Allergy Asthma Proc 2005, 26:435-9.
26. Limb SL, Starke PR, Lee CE, et al. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007, 120:1378-81. 10.1016/j.jaci.2007.09.022, 17936893.
27. Barry PJ, O'Mahony A, Finnegan C, et al. Delayed allergic reactions to omalizumab: are patients reporting all cases?. J Allergy Clin Immunol 2008, 121:785-6. 10.1016/j.jaci.2007.12.1184, 18328902.
28. Price KS, Woodard L, Pingle L, et al. Anaphylaxis to Omalizumab after 14 Months of Successful Therapy. J Allergy Clin Immunol 2006, 117(2 Suppl 1):S10. [abstract].
29. Liebhaber M, Dyer Z. Home Therapy with Subcutaneous Anti-Immunoglobulin-E Antibody Omalizumab in 25 Patients with Immunoglobulin-E-Mediated (Allergic) Asthma. J Asthma 2007, 44:195-6. 10.1080/02770900701209749, 17454337.
30. Confino-Cohen R, Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study. Ann Allergy Asthma Immunol 2010, 104:73-8. 10.1016/j.anai.2009.11.001, 20143649.
31. Ewan PW. Anaphylaxis. BMJ 1998, 316:1442-5. 1113119, 9572760.
32. Lin RY. A perspective on penicillin allergy. Arch Intern Med 1992, 15:930-7.
33. de Weck A, Sanz ML, Gamboa P. [New pathophysiological concepts on aspirin hypersensitivity (Widal syndrome); diagnostic and therapeutic consequences]. Bull Acad Natl Med 2005, 189:1201-18.
34. Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988, 260:967-70. 10.1001/jama.260.7.967, 2840522.
35. Schellenberg R, Adachi JD, Bowie D, et al. Oral corticosteroids in asthma: A review of benefits and risks. Can Respir J 2007, 14(Suppl C):1C-7C.